Renal cell carcinoma - The Lancet

Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study - The Lancet Oncology

Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study - The Lancet Oncology

Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial - The Lancet Oncology

Renal cell carcinoma - The Lancet

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology

Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial - The Lancet Oncology

Metastatic renal cell carcinoma to the pancreas and other sites—a multicenter retrospective study - eClinicalMedicine

Renal cancer - The Lancet

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial - The Lancet

Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial - The Lancet Oncology

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial - The Lancet

Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial - The Lancet Oncology

Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial - The Lancet Oncology

Comparative analyses define differences between BHD-associated renal tumour and sporadic chromophobe renal cell carcinoma - eBioMedicine

Renal cell carcinoma Nature Reviews Disease Primers